Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looking for $5 short term on TSPT
Huge news AH on TSPT
ttp://finance.yahoo.com/news/Transcept-Pharmaceuticals-prnews-1578793491.html?x=0&.v=1
ANX $1.06 + .14 Vista issues $7.50 price target
http://finance.yahoo.com/news/Vista-Partners-Updates-prnews-2255990751.html?x=0&.v=1
ANX is best buy on AMEX. $1.07 with $1.6 per share cash, no debt, and 3 blocbuster drug candidates. Was $4 a few months ago.
Also the largest US Hedge Fund, Blackrock, reported a 5% stake Friday.
ANX $1.06 + .14 Vista issues $7.50 price target
http://finance.yahoo.com/news/Vista-Partners-Updates-prnews-2255990751.html?x=0&.v=1
ANX is best buy on AMEX. $1.07 with $1.6 per share cash, no debt, and 3 blocbuster drug candidates. Was $4 a few months ago.
Also the largest US Hedge Fund, Blackrock, reported a 5% stake Friday.
ANX $1.06 + .14 Vista issues $7.50 price target
http://finance.yahoo.com/news/Vista-Partners-Updates-prnews-2255990751.html?x=0&.v=1
ANX is best buy on AMEX. $1.07 with $1.6 per share cash, no debt, and 3 blocbuster drug candidates. Was $4 a few months ago.
Also the largest US Hedge Fund, Blackrock, reported a 5% stake Friday.
30 Million LMLP settles with Fargo
LMLP just settled with Wells Fargo on patent infringement. Based on LMLP prior settlements with other banks, the settlement should be about $30 million.
JOINT NOTICE OF SETTLEMENT AND MOTION TO STAY
LML Patent Corp., Wells Fargo Bank, N.A., and Wachovia Bank n/k/a Wells Fargo
Bank, N.A. jointly and respectfully notify the Court that the parties, as a result of the Court ordered mediation, have reached an agreement to settle this case subject to the drafting andc executing of a written settlement and license agreement acceptable to both parties.
In nearly every LML settlement news release it states they used the defendants ACH volume as their basis. Here are the 2010 volumes of the top 25 ACH processors. Citigroup settled for $7.5 MM and Wells Fargo has 4 times more ACU transactions.
Largest Financial Institution Originators of Automated Clearing House Payments, Year 2010*
Rank Company ****** Totals
1 J.P. Morgan Chase & Co 3,174,064,104
2 Wells Fargo & Company 3,028,937,735
3 Bank of America Corporation 1,934,229,757
4 Citigroup, Inc. 787,561,212
LF: NYSE dirt cheap launching baby Ipad
LF is the best buy on the market right now IMO.
Profitable. $2.4 per share current assets and no debt.
http://finance.yahoo.com/q/bs?s=LF+Balance+Sheet&annual
Is launchinhg the updated Leap pad this month (an IPad for kids). Pre market sales and reviews have been huge.
I think they will blow away their $.20 annual EPS forecast.
TSPT $3.05, $4.5 per share cash, 6 MM float
Looks good for a quick bounce back to $4.50.
Insiders just bought yesterday, FDA meeting scheduled for September.
Why ANX will bounce back QUICKLY to $2 IMO: The price drop yesterday was totally irrational. ANX deserves a MIMINUM $2.50 share price.
-ANX has $1.59 per share cash, no debt and a very low cash burn rate.
-The market opportunity for the the company's other drugs (ANX188 and ANX544) is much larger.
-With a $30 MM market cap and $42 MM cash, the market is assigning ZERO value to these other drugs.
- The CEO stated in the conference call that ANX has many options going forward (partnerships) and ANX will look like a much different company in 2012.
-ANX was trading in the $10 range in 2009 and is now in MUCH better shape with $42 million cash than it was then.
-ANX is trading at a huge discount to other biotechs with late stage Phase 2 drugs.
YMI, ZLCS and AEZS have well over $100 MM marker caps.
In short, the prospects for ANX's major drug candidates remain intact. Todays selloff based on rejection of a minor "niche" drug, Exelbine, lowpresents a compelling buying opportunity.
$2 short term target.
Why ANX ($1.06 - 1.45) will bounce back QUICKLY to $2 IMO: The price drop yesterday was totally irrational. ANX deserves a MIMINUM $2.50 share price.
-ANX has $1.59 per share cash, no debt and a very low cash burn rate.
-The market opportunity for the the company's other drugs (ANX188 and ANX544) is much larger.
-With a $30 MM market cap and $42 MM cash, the market is assigning ZERO value to these other drugs.
- The CEO stated in the conference call that ANX has many options going forward (partnerships) and ANX will look like a much different company in 2012.
-ANX was trading in the $10 range in 2009 and is now in MUCH better shape with $42 million cash than it was then.
-ANX is trading at a huge discount to other biotechs with late stage Phase 2 drugs.
YMI, ZLCS and AEZS have well over $100 MM marker caps.
In short, the prospects for ANX's major drug candidates remain intact. Todays selloff based on rejection of a minor "niche" drug, Exelbine, lowpresents a compelling buying opportunity.
$2 short term target.
BLTI was up nearly 30% today at one point. Going to $5 short term IMO
Laser dentistry equipment supplier BLTI was the strongest NASDAQ stock today. It is down 50% from its highs in the $7 range and IMO will quickly bounce back to $5.
-Small tightly held 25 million float.
-Insiders recently bought above $4.
-Institutions recently invested in private placement above $5.
-BLTI has over 100 patents. BLTI technology has many other potential applications (dermatology).
-BLTI is in better shape that in 2007 when it traded in $8 range. Selling expenses have been cut in half, and the company now has very healthy balance sheet.
-BLTI is heading into strongest part of year. Most sales are in Q4.
-BLTI is cash flow positive now based mainly on domestic sales, international sales now gearing up (India, China).
- The two top US hedge funds, Blackrock and Renaiisance, own big posistions.
-BLTI at one point rose 30% during the worst market day of 2011. That tells you all you need to know.
BLTI was up nearly 30% today at one point. Going to $5 short term IMO
Laser dentsitry equipment supplier BLTI was the strongest NASDAQ stock today. It is down 50% from its highs in the $7 range and IMO will quickly bounce back to $5.
-Small tightly held 25 million float.
-Insiders recently bought above $4.
-Institutions recently invested in private placement above $5.
-BLTI has over 100 patents. BLTI technology has many other potential applications (dermatology).
-BLTI is in better shape that in 2007 when it traded in $8 range. Selling expenses have been cut in half, and the company now has very healthy balance sheet.
-BLTI is heading into strongest part of year. Most sales are in Q4.
-BLTI is cash flow positive now based mainly on domestic sales, international sales now gearing up (India, China).
- The two top US hedge funds, Blackrock and Renaiisance, own big posistions.
-BLTI at one point rose 30% during the worst market day of 2011. That tells you all you need to know.
$5 short term.
PATH Migraine NDA submission August 29
PATH has a 4.5 MM float, $70 MM market cap and $32 MM cash.
PATH has a very promising Migrine treatment. It is just as effective and safer than the inhaled drug being developed by MAPP, which has a $400 MM market cap.
For folks looking for a short term rebound play PATH could go higher very quickly.
PATH was in the $7 - $ range until a few days ago but dropped to $3.30 at the low but bounced back to $4.85 Friday. The drop was totally irrational, they announced a financing facility that could be used in the future, but have not issued one new share.
EFOI:NASDAQ $23 Million Contract $.59 + $.18
http://www.wkyc.com/news/article/200632/3/Solon-company-receives-23M-federal-contract-?odyssey=mod|newswell|text|FRONTPAGE|t
EFOI has a small float and was over $2 last year. Biggest contract in its history.
EFOI:NASDAQ $23 Million Contract $.59 + $.18
http://www.wkyc.com/news/article/200632/3/Solon-company-receives-23M-federal-contract-?odyssey=mod|newswell|text|FRONTPAGE|t
EFOI has a small float and was over $2 last year. Biggest contract in its history.
SIHI:NASDAQ $1.35, 2 PE. Last insanely cheap China stock
SIHI moving. 7 Million float
SIHI:NASDAQ $1.35, 2 PE. Last insanely cheap China stock
SIHI moving. 7 Million float
RXII ($1.38) has traded at a huge discount to fair value because it has been under the radar, but not for long. Recent articles in Barrons and Seeking Alpha have have identified RXII as a biotech laggard with huge potential.
RXII'S NEUVAX CANCER VACCINE RESULTS ARE UNPRECEDENTED.
BASED ON 3 YEARS OF DATA, THE VACCINE REDUCED THE BREAST CANCER RECURRANCE RATE FROM 22% TO 0%.
http://finance.yahoo.com/news/RXi-Pharma...
THE RXII VACCINE IS MORE EFFECTIVE THAN DNDN PROVENGE.
DNDN HAS A $5.6 BILLION MARKET CAP.
The vaccine was so effective in Phase 2 that the FDA granted a Special Protocol Assessment for Phase 3.
RXII has $25 MM cash and a $55 MM market cap, meaning the market is valuing its technology at $30 million. The current market cap does not reflect the $5 billion market potential of RXII's Neuvax cancer vaccine.
The potential market for a breast cancer vaccine is staggering. Only 25% of all breast cancer patients, those with HER2 3+ disease are eligible for Herceptin which had 2010 revenues of over $5 billion. NeuVax targets the remaining 50% of HER2 positive patients.
RXII trades at a huge discount to other cancer vaccine stocks with no proven effacacy. In 2007 GNVC rose to a a $250 million market cap based on a cancer vaccine prospect. AGEN currently has a $100 million market cap.
Roth Capital has a $4 target for RXII, which would reflect a $120 million market cap. The most successful US Hedge Funds, Renaissance Technologies and Blackrock, hold RXII.
RXII ($1.38)
RXII has traded at a huge discount to fair value because it has been under the radar, but not for long. Recent articles in Barrons and Seeking Alpha have have identified RXII as a biotech laggard with huge potential.
RXII'S NEUVAX CANCER VACCINE RESULTS ARE UNPRECEDENTED.
BASED ON 3 YEARS OF DATA, THE VACCINE REDUCED THE BREAST CANCER RECURRANCE RATE FROM 22% TO 0%.
http://finance.yahoo.com/news/RXi-Pharma...
THE RXII VACCINE IS MORE EFFECTIVE THAN DNDN PROVENGE.
DNDN HAS A $5.6 BILLION MARKET CAP.
The vaccine was so effective in Phase 2 that the FDA granted a Special Protocol Assessment for Phase 3.
RXII has $25 MM cash and a $55 MM market cap, meaning the market is valuing its technology at $30 million. The current market cap does not reflect the $5 billion market potential of RXII's Neuvax cancer vaccine.
The potential market for a breast cancer vaccine is staggering. Only 25% of all breast cancer patients, those with HER2 3+ disease are eligible for Herceptin which had 2010 revenues of over $5 billion. NeuVax targets the remaining 50% of HER2 positive patients.
RXII trades at a huge discount to other cancer vaccine stocks with no proven effacacy. In 2007 GNVC rose to a a $250 million market cap based on a cancer vaccine prospect. AGEN currently has a $100 million market cap.
Roth Capital has a $4 target for RXII, which would reflect a $120 million market cap. The most successful US Hedge Funds, Renaissance Technologies and Blackrock, hold RXII.
RXII ($1.38) going to go parabolic
RXII has traded at a huge discount to fair value because it has been under the radar, but not for long. Recent articles in Barrons and Seeking Alpha have have identified RXII as a biotech laggard with huge potential.
RXII'S NEUVAX CANCER VACCINE RESULTS ARE UNPRECEDENTED.
BASED ON 3 YEARS OF DATA, THE VACCINE REDUCED THE BREAST CANCER RECURRANCE RATE FROM 22% TO 0%.
http://finance.yahoo.com/news/RXi-Pharma...
THE RXII VACCINE IS MORE EFFECTIVE THAN DNDN PROVENGE.
DNDN HAS A $5.6 BILLION MARKET CAP.
The vaccine was so effective in Phase 2 that the FDA granted a Special Protocol Assessment for Phase 3.
RXII has $25 MM cash and a $55 MM market cap, meaning the market is valuing its technology at $30 million. The current market cap does not reflect the $5 billion market potential of RXII's Neuvax cancer vaccine.
The potential market for a breast cancer vaccine is staggering. Only 25% of all breast cancer patients, those with HER2 3+ disease are eligible for Herceptin which had 2010 revenues of over $5 billion. NeuVax targets the remaining 50% of HER2 positive patients.
RXII trades at a huge discount to other cancer vaccine stocks with no proven effacacy. In 2007 GNVC rose to a a $250 million market cap based on a cancer vaccine prospect. AGEN currently has a $100 million market cap.
Roth Capital has a $4 target for RXII, which would reflect a $120 million market cap. The most successful US Hedge Funds, Renaissance Technologies and Blackrock, hold RXII.
Top 10 Reasons to ATRN vs. Pandora
10 Reasons to Buy Kazaa/ATRN vs. Pandora or SIRI
1) Facebook Music Dashboard2) Market Cap - Pandora - $2.5B vs. Kazaa - $15m
3) Float - Pandora Float 14.7m / Kazaa Float 1.1 million
4) Short Squeeze - Kazaa has 400k+ of 1m float sold short
5) Kazaa just hired Rock Star CEO
6) Kazaa iPhone App to be launched within days.
7) Kazaa Radio just went live though not announced yet.
8) Director stepped down to get more Kazaa/ATRN shares
9) Kazaa has "on demand" licenses worth over $100m paid for
10) If 10% of Pandora trading volume moves to Kazaa......
1) Facebook Music Dashboard will make Kazaa Subs grow from 100k to 1 million by Christmas and maybe more..Look what happened to Zynga, PopCap, Playdom and the gaming companies when Facebook launched its Gaming operation. How many of Facebook's 750 million users were also one of the 800 million who downloaded the original Kazaa? Kazaa the only Dashboard player with US consumer name/brand recognition.
2) Pandora's market cap is $2.5 billion and any significant increase in the next 30 days will be solely due to a short squeeze due to a smallish float. Kazaa/ATRN's market cap is $15 million due to zero investor recognition that Atrinsic is now Kazaa and its "on demand" licenses alone are worth over $100 million.
3) Kazaa (ATRN) float is 1.13 million shares officially, but its "true public float" is said to be closer to 600k. Pandora is said to have a small float at 14.7m shares.
4) 400,000 shares of Kazaa are sold short as of Friday's Nasdaq report. Pandora is said to have a small float at 14.7m shares and it is benefiting from a short squeeze. Have you ever heard of a Nasdaq listed company with a float of 1 million or less? With 400,000 shares sold short?
5) Kazaa just hired a rock stock CEO - Stuart Goldfarb, who transitioned BMG Music Club and Columbia House from failing mail order business to thriving dot com, selling billions of dollars worth of music per year through online subscription clubs. No executive has ever presided over the sale of subscription music sales than Goldfarb. His company's music sales over the last decade are the only significant challenger to Apple's music sales and it would be substantially more than Rhapsody, Spotify and every other subscription music seller put together. He also brought his Chief Marketing Officer to Kazaa with him.
6) Kazaa may launch its iPhone App in days, said to be launched before end of Q2.
7) Kazaa Radio went live a couple of weeks ago, not announced by co. yet. Kazaa radio is like Pandora, but pulls from catalog of 5 million songs vs. Pandora's 800k.
8) While Pandora directors sell stock, Kazaa actually had a director leave the board so he could make unrestricted open market purchases. Robert Ellin filed a 13d late last week showing he started buying more (added 2% of KAzaa's shares outstanding) over the last few weeks and appears to be buying daily since the expiration of 60 days from his resignation.
9) Kazaa has "on demand" licenses with the Big 4 that are worth over $100m. Kazaa paid $115m for the licenses in 2007 and Spotify, Apple & Google were all asked to pay closer to $150m for them over the last few months.
10) If 5% of the traders (volume) in Pandora brought that capital to Kazaa, the stock could easily move over $10 in a week.
I actually borrowed this from the Pandora board. Full credit where its due
ATRN explodes tomorrow: Seeking Alpha Article, Pandora IPO, 2 MM float
Theres mixed speculation about Pandora's IPO tomorrow - mainly due to the lack of profitability. But you cant use fundamentals to determine pricepoints for IPOs like Pandora. Potential and momentum are the keys here.
Tonight they price it - likely around $12/sh. Also 14M shares will be available to trade. The beauty of these markets is that they are so momentum driven, many saw LNKD results (up from $45 to $120 in hours) and expect a similar start. Traders have similar expectations tomorrow for P.
Trading starts about 10:30 EST tomorrow for P. I look for it to open in the high teens and trade in the 20s tomorrow before settling. As a result, ATRN trades to $4-5 just on a sympathy renevue multiple alone. Could be highers if the daytraders start working it.
http://seekingalpha.com/article/274900-is-pandora-worth-2-billion?source=yahoo
PLUGD exploding trades $.22 pre reverse split price
PLUGD is poised to move much higher in the short term and long term.
-Insiders bought at $2.42.
-Trading at 20% of 52 week highs.
-In hot sector.
-Small 20 million float.
-$30 million cash with $44 million market cap. Market valuing the non cash assets at $14 million.
-Trading at huge discount to others in the sector.
-Revenue is exploding. $35 - $45 million revenue forecast for 2011. Further 80% growth forecast for 2012.
Cash flow positive forecast for 2012.
-Many fortune 500 customers including WalMart and Coca Cola
PEIXD, PLUGD dirt cheap RS plays.
Have both. PLUGD is my favoritr.
Insiders bought at $2.42.
-Trading at 20% of 52 week highs
-In hot sector.
-Small 20 million float.
-$30 million cash with $44 million market cap. Market valuing the non cash assets at $14 million.
-Trading at huge discount to others in the sector.
PLUGD is a dream stock. $5 soon.
-Insiders bought at $2.42.
-Trading at 20% of 52 week highs
-In hot sector.
-Small 20 million float.
-$30 million cash with $44 million market cap. Market valuing the non cash assets at $14 million.
-Trading at huge discount to others in the sector.
PLUGD is a dream stock. $5 soon.
-Insiders bought at $2.42.
-Trading at 20% of 52 week highs
-In hot sector.
-Small 20 million float.
-$30 million cash with $44 million market cap. Market valuing the non cash assets at $14 million.
-Trading at huge discount to others in the sector.
ATRN 2 MM float will explode next week
Pandora IPO will give huge boost to ATRN. Also, ATRN will release GOOGLE and android apps soon.
Oakland-based Pandora Media intends to go public June 14, according to a regulatory filing and a report from Renaissance Capital. The Internet radio company could raise up to $123 million through the initial public offering of its stock. The share price is expected to range from $7 to $9 each. At a mid-point of $8, Pandora would have a market value of $1.27 billion.
Kazaa Update
The Company’s short term product strategy is to release iPhone and Android apps, expand its music library beyond the five million tracks and albums it has already licensed and continue to offer users competitive pricing plans and unique billing alternatives.
http://finance.yahoo.com/news/Atrinsic-Reports-Operating-bw-2665237176.html?x=0&.v=1
Maybe, but 10 different sub groups in the Phase 2 24 month data all had remarkable results.
Fluke?
I think not. Even if it were questionable, it will still be a great momentum play.
RXII ASCO results: 100% effective vaccine.
The 36 month results are astonisihing. Vaccine reduced the Breast Cancer recuurance rate from 12.5% to ZERO.
You read that correctly!!
"In contrast, 30 patients received either E75 (12) or X (18) + GM-CSF after completing adjuvant Tz, with a recurrence rate of 0% (0/30) (p=0.065)."
http://abstract.asco.org/AbstView_102_84...
Abstract:
Background: We are conducting multiple, prospective, phase II trials evaluating different HER-2/neu (HER2) peptide vaccines in the adjuvant setting to prevent breast cancer (BrCa) recurrence. E75 (HER2: 369-377) and another vaccine (X) are HLA-A2/3+-restricted peptides capable of stimulating CD8+ cytotoxic T cells with anti-HER2 tumor activity. Trastuzumab (Tz), a recombinant monoclonal anti-HER2 antibody, has been shown to reduce BrCa recurrence by 50%. We examined the sequential use of Tz and a CD8 T cell-eliciting vaccine to compare the efficacy of sequential passive and active immunization to passive immunotherapy alone. Methods: We examined patients from our E75 and vaccine X clinical trials. HLA-A2/3+ node positive or high-risk node negative BrCa patients with any level of HER2 expression, disease-free after standard treatments were vaccinated with E75 or X+GM-CSF (immunoadjuvant) vs. nothing (E75 trial) or GM-CSF alone (X trial). Vaccinations were given as 6 monthly intradermal inoculations. Patients receiving adjuvant Tz followed by vaccination were compared to those receiving Tz without vaccination (or GM-CSF alone). p-values were calculated using Fisher’s exact test. Results: Of 283 patients (E75=187; 108 vaccine, 79 control) (X=96; 41 vaccine, 55 control), 62 (22%) received adjuvant Tz (E75=15, X=47). Of the 62 Tz-treated patients, 32 received no vaccine, and their recurrence rate is 12.5% (4/32)—comparable with reported rates of similarly staged and treated patients. In contrast, 30 patients received either E75 (12) or X (18) + GM-CSF after completing adjuvant Tz, with a recurrence rate of 0% (0/30) (p=0.065). Overall median length of follow-up is 48 months (E75=57 mo, X=19 mo). Conclusions: BrCa patients enrolled in our phase II trials of the E75 or X peptide vaccines who received adjuvant Tz followed by vaccination with a CD8-eliciting peptide vaccine appear to have a lower recurrence rate than adjuvant Tz therapy alone. This finding suggests that the combination of passive and active HER-2/neu immunization may have better efficacy than passive immunotherapy alone and has prompted the initiation of combination clinical trials.
RXII ASCO results: 100% effective vaccine.
The 36 month results are astonisihing. Vaccine reduced the Breast Cancer recuurance rate from 12.5% to ZERO.
You read that correctly!!
"In contrast, 30 patients received either E75 (12) or X (18) + GM-CSF after completing adjuvant Tz, with a recurrence rate of 0% (0/30) (p=0.065)."
http://abstract.asco.org/AbstView_102_84...
Abstract:
Background: We are conducting multiple, prospective, phase II trials evaluating different HER-2/neu (HER2) peptide vaccines in the adjuvant setting to prevent breast cancer (BrCa) recurrence. E75 (HER2: 369-377) and another vaccine (X) are HLA-A2/3+-restricted peptides capable of stimulating CD8+ cytotoxic T cells with anti-HER2 tumor activity. Trastuzumab (Tz), a recombinant monoclonal anti-HER2 antibody, has been shown to reduce BrCa recurrence by 50%. We examined the sequential use of Tz and a CD8 T cell-eliciting vaccine to compare the efficacy of sequential passive and active immunization to passive immunotherapy alone. Methods: We examined patients from our E75 and vaccine X clinical trials. HLA-A2/3+ node positive or high-risk node negative BrCa patients with any level of HER2 expression, disease-free after standard treatments were vaccinated with E75 or X+GM-CSF (immunoadjuvant) vs. nothing (E75 trial) or GM-CSF alone (X trial). Vaccinations were given as 6 monthly intradermal inoculations. Patients receiving adjuvant Tz followed by vaccination were compared to those receiving Tz without vaccination (or GM-CSF alone). p-values were calculated using Fisher’s exact test. Results: Of 283 patients (E75=187; 108 vaccine, 79 control) (X=96; 41 vaccine, 55 control), 62 (22%) received adjuvant Tz (E75=15, X=47). Of the 62 Tz-treated patients, 32 received no vaccine, and their recurrence rate is 12.5% (4/32)—comparable with reported rates of similarly staged and treated patients. In contrast, 30 patients received either E75 (12) or X (18) + GM-CSF after completing adjuvant Tz, with a recurrence rate of 0% (0/30) (p=0.065). Overall median length of follow-up is 48 months (E75=57 mo, X=19 mo). Conclusions: BrCa patients enrolled in our phase II trials of the E75 or X peptide vaccines who received adjuvant Tz followed by vaccination with a CD8-eliciting peptide vaccine appear to have a lower recurrence rate than adjuvant Tz therapy alone. This finding suggests that the combination of passive and active HER-2/neu immunization may have better efficacy than passive immunotherapy alone and has prompted the initiation of combination clinical trials.
NEI:NASDAQ $1.17. A no brainer.
NEI is the best buy on NASDAQ.
-Trading below net working capital per share.
-Profitable.
-In a hot sector, storage.
-Only reason NEI went down was loss of low margin EMC contract. In last CC CEO stated many new contracts coming, and will remain profitable.
$2 by June 30.
NEI $1.22 + $.14 was $2 a few weeks ago, profitable storage stock.
Overeaction on losing low margin EMC account, CEO said many new contracts coming and will stay profitable. In hot storage space.
http://finance.yahoo.com/q/ecn?s=NEI+Order+Book
RXII $1.25 + $.16 $4 Roth Target
RXII has $20 MM cash and a $35 MM market cap, meaning the market is valuing its technology at $15 million. The current market cap does not reflect the $5 billion market potential of RXII's Neuvax cancer vaccine.
RXII Cancer Vaccine results are unprecedented. The vaccine was so effective in Phase 2 trials that the FDA granted a SPA for a Phase 3 Trial.
BASED ON 2 YEARS OF DATA, THE RXII CANCER VACCINE REDUCED THE BREAST CANCER RECURRANCE RATE FROM 14.5% TO 2.7%. Updated 3 years results will be presented at ASCO.
The potential market for a breast cancer vaccine is staggering. Only 25% of all breast cancer patients, those with HER2 3+ disease are eligible for Herceptin which had 2010 revenues of over $5 billion. NeuVax targets the remaining 50% of HER2 positive patients.
RXII trades at a huge discount to other cancer vaccine stocks with no proven effacacy. In 2007 GNVC rose to a a $250 million market cap based on a cancer vaccine prospect. AGEN currently has a $100 million market cap.
Roth Capital has a $4 target for RXII, which would reflect a $120 million market cap.
RXII:NASDAQ $1.25 + $.16 $4 Roth Capital Target
RXII has $20 MM cash and a $35 MM market cap, meaning the market is valuing its technology at $15 million. The current market cap does not reflect the $5 billion market potential of RXII's Neuvax cancer vaccine.
RXII Cancer Vaccine results are unprecedented. The vaccine was so effective in Phase 2 trials that the FDA granted a SPA for a Phase 3 Trial.
BASED ON 2 YEARS OF DATA, THE RXII CANCER VACCINE REDUCED THE BREAST CANCER RECURRANCE RATE FROM 14.5% TO 2.7%. Updated 3 years results will be presented at ASCO.
The potential market for a breast cancer vaccine is staggering. Only 25% of all breast cancer patients, those with HER2 3+ disease are eligible for Herceptin which had 2010 revenues of over $5 billion. NeuVax targets the remaining 50% of HER2 positive patients.
RXII trades at a huge discount to other cancer vaccine stocks with no proven effacacy. In 2007 GNVC rose to a a $250 million market cap based on a cancer vaccine prospect. AGEN currently has a $100 million market cap.
Roth Capital has a $4 target for RXII, which would reflect a $120 million market cap.
RXII + 12% to $1.09. DD Summary:
RXII has $20 MM cash and a $35 MM market cap, meaning the market is valuing its technology at $15 million. The current market cap does not reflect the $5 billion market potential of RXII's Neuvax cancer vaccine.
RXII Cancer Vaccine results are unprecedented. The vaccine was so effective in Phase 2 trials that the FDA granted a SPA for a Phase 3 Trial.
BASED ON 2 YEARS OF DATA, THE RXII CANCER VACCINE REDUCED THE BREAST CANCER RECURRANCE RATE FROM 14.5% TO 2.7%. Updated 3 years results will be presented at ASCO.
The potential market for a breast cancer vaccine is staggering. Only 25% of all breast cancer patients, those with HER2 3+ disease are eligible for Herceptin which had 2010 revenues of over $5 billion. NeuVax targets the remaining 50% of HER2 positive patients.
RXII trades at a huge discount to other cancer vaccine stocks with no proven effacacy. In 2007 GNVC rose to a a $250 million market cap based on a cancer vaccine prospect. AGEN currently has a $100 million market cap.
Roth Capital has a $4 target for RXII, which would reflect a $120 million market cap.
RXII $1.01 +.03 30 MM market cap ASCO Cancer vaccine Blockbuster results
I called OXGN at $1.80. I think RXII is the next special situation biotech that could triple in a very short time frame. RXII has one of the most promising cancer vaccines, with SPA status and a potential $5 billion market.
RXII has been undiscovered but not for long. RXII CANCER VACCINE REDUCED BREAST CANCER RECURRANCE FROM 14% TO 2% (2 YEARS OF DATA). 3 year results presented at ASCO.
RXII has $20 MM cash and a $30 MM market cap, meaning the market is valuing its technology at $10 million.
Other junior biotechs in the cancer vaccine space like AGEN:NASDAQ have minimum $100 MM ++ market caps.
RXII $1.01 +.03 30 MM market cap ASCO Cancer vaccine Blockbuster results
I called OXGN at $1.80. I think RXII is the next special situation biotech that could triple in a very short time frame. RXII has one of the most promising cancer vaccines, with SPA status and a potential $5 billion market.
RXII has been undiscovered but not for long. RXII CANCER VACCINE REDUCED BREAST CANCER RECURRANCE FROM 14% TO 2% (2 YEARS OF DATA). 3 year results presented at ASCO.
RXII has $20 MM cash and a $30 MM market cap, meaning the market is valuing its technology at $10 million.
Other junior biotechs in the cancer vaccine space like AGEN:NASDAQ have minimum $100 MM ++ market caps.
RXII $.98 ASCO Blockbuster results
RXII could be $3 in no time like ZLCS and ACAD. RXII has a blockbuster cancer vaccine with unprecedented results approved for an SPA.
The vaccine reduced breast cancer recurrance from 14% to 2%. ober a 2 year period.
That trumps DNDN.
Updated results at ASCO.
Only 30 MM float and $20 MM cash. Market valuing thus vaccine at basically 0.
RXII $.98 ASCO Blockbuster results
RXII could be $3 in no time like ZLCS and ACAD. RXII has a blockbuster cancer vaccine with unprecedented results approved for an SPA.
The vaccine reduced breast cancer recurrance from 14% to 2%. ober a 2 year period.
That trumps DNDN.
Updated results at ASCO.
Only 30 MM float and $20 MM cash. Market valuing thus vaccine at basically 0.
RXII $.98 ASCO Blockbuster results
RXII could be $3 in no time like ZLCS and ACAD RXII has a blockbuster cancer vaccine with unprecedented results approved for an SPA.
The vaccine reduced breast cancer recurrance from 14% to 2%.
That trumps DNDN.
Updated results at ASCO.